To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

Inclusion Criteria: * Postmenopausal women who can walk freely (≥50 and ≤85 years); * The patient has a body mass index(BMI) of 17.0 kg/m2 to 30 kg/m2； * The patient has a bone mineral density T-score≤-2.5 and \> -5.0 at the lumbar spine (L1-L4) or femoral neck or total hip by dual energy x-ray absorptiometry (DXA)； * The patient has at least one of the following high risk factors of fracture: 1) history of previous fragility fractures; 2) family history of hip fragility fracture; 3) age≥70 years; 4) BMI≤19.0 kg/m2；5) Currently smoking. * The patient with at least 2 consecutive vertebrae(L1 to L4) and at least 1 hip can be evaluated for BMD. Exclusion Criteria: * In addition to postmenopausal osteoporosis, the other diseases affecting bone metabolism； * History of osteosarcoma； * History of orthostatic hypotension； * Currently suffering from active urinary calculus； * Received anti-osteoporosis treatment that does not meet protocol requirements； * Received medication that affects bone metabolism within 4 weeks prior to screening, or is planned to use prohibited drugs/non-drug therapy under the protocol during the study period.